Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600276 Jiangsu Hengrui Pharmaceuticals Co.,Ltd.

Closed 12-20 15:00:00

46.25

-0.29

-0.62%

High46.88	Low46.22	Vol26.07M
Open46.54	D1 Closing46.54	Amplitude1.42%
Mkt Cap295.03B	Tradable Cap295.03B	Total Shares6.38B
T/O1.21B	T/O Rate0.41%	Tradable Shares6.38B
P/B6.74	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.","latestPrice":46.25,"timestamp":1734678000000,"preClose":46.54,"halted":0,"volume":26073276,"delay":0,"changeRate":-0.0062,"floatShares":6379000000,"shares":6379000000,"eps":0.8541,"marketStatus":"Closed","change":-0.29,"latestTime":"12-20 15:00:00","open":46.54,"high":46.88,"low":46.22,"amount":1213000000,"amplitude":0.0142,"askPrice":46.28,"askSize":1,"bidPrice":46.25,"bidSize":700,"shortable":0,"etf":0,"ttmEps":0.8541,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1734917400000},"marketStatusCode":5,"adr":0,"adjPreClose":46.54,"symbolType":"stock","openAndCloseTimeList":[[1734658200000,1734665400000],[1734670800000,1734678000000]],"highLimit":51.19,"lowLimit":41.89,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6379002274,"isCdr":false,"pbRate":6.74,"roa":"--","peRate":54.150568,"roe":"10.88%","epsLYR":0.68,"committee":0.646977,"marketValue":295029000000,"turnoverRate":0.0041,"status":1,"floatMarketCap":295029000000},"requestUrl":"/m/hq/s/600276/wiki","defaultTab":"wiki","newsList":[{"id":"2492117111","title":"Jiangsu Hengrui Medicine Gets China Green Light for Bladder Cancer Drug Combo","url":"https://stock-news.laohu8.com/highlight/detail?id=2492117111","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492117111?lang=en_us&edition=fundamental","pubTime":"2024-12-19 15:30","pubTimestamp":1734593405,"startTime":"0","endTime":"0","summary":"China approved the clinical trial of Jiangsu Hengrui Medicine  units Shanghai Hengrui Medicine and Shanghai Shengdi Pharmaceutical for the SHR-1501 and adebelimumab injections, according to a Thursday filing with the Shanghai Stock Exchange.The combination of SHR-1501 and adebelimumab are indicated for clinical trials for non-muscle-invasive bladder cancer, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2492601320","title":"Hengrui Medicine's Unit Included In Chinese Drug Administration's Breakthrough Therapy Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=2492601320","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492601320?lang=en_us&edition=fundamental","pubTime":"2024-12-17 12:11","pubTimestamp":1734408689,"startTime":"0","endTime":"0","summary":"A drug of Jiangsu Hengrui Medicine's  unit, Suzhou Shengdia Biopharmaceutical, was included in the proposed breakthrough therapy products list of China's National Medical Products Administration.The drug is trastuzumab for injection, a drug used to treat patients with ovarian cancer and primary peritoneal cancer, according to a Shanghai Stock Exchange disclosure on Monday.The drug will be included in the regulator's breakthrough therapy program, the pharmaceutical company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","LU1064131003.USD","BK0028","BK0239","BK0188","LU1064130708.USD","LU2488822045.USD","BK0012","LU2148510915.USD","BK0196","600276","LU0405327148.USD","LU1328615791.USD","LU0405327494.USD","BK0060"],"gpt_icon":0},{"id":"2491635651","title":"Hengrui Medicine Gets Nod to Trial Lupus Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2491635651","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491635651?lang=en_us&edition=fundamental","pubTime":"2024-12-16 12:30","pubTimestamp":1734323428,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  will conduct clinical trials on SHR-2173 injection after receiving approval from the Chinese drug administration, according to a Shanghai Stock Exchange filing on Friday.The drug will be tested as a treatment for lupus nephritis, the pharmaceutical company said.Hengrui Medicine's shares slipped more than 1% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2490829689","title":"Jiangsu Hengrui Medicine Gets Clinical trial Approval for Weight Loss Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2490829689","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490829689?lang=en_us&edition=fundamental","pubTime":"2024-12-12 13:14","pubTimestamp":1733980447,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  and subsidiary Fujian Shengdi Pharmaceutical secured the approval of China's drug administrator to conduct clinical trials for HRS-4729 injection.HRS-4729, which can potentially regulate glucose and lipid metabolism as well as suppress appetite, will be clinically tested in obese or overweight patients, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company declined less than 1% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2490004468","title":"Jiangsu Hengrui Medicine's Subsidiaries Get Regulatory Nod to Trial Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2490004468","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490004468?lang=en_us&edition=fundamental","pubTime":"2024-12-11 12:30","pubTimestamp":1733891448,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine's  subsidiaries, Shandong Shengdi Pharmaceutical and Jiangsu Hengrui Medicine, will conduct clinical trials on HRS-3802 sustained-release tablets after receiving approval from China's National Medical Products Administration, according to a Shanghai Stock Exchange disclosure on Tuesday.The drug will be tested as a treatment for advanced malignant solid tumors.The pharmaceutical company invested 10.3 million yuan into the research and development of the drug, the disclosure said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0405327494.USD","LU1064130708.USD","LU1064131003.USD","BK0239","LU2148510915.USD","BK0028","BK0012","600276","BK0196","BK0188","BK0060","LU0405327148.USD","BK0183","LU1328615791.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2490741580","title":"Hengrui Pharmaceuticals  Says It Plans to Seek Hong Kong Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2490741580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490741580?lang=en_us&edition=fundamental","pubTime":"2024-12-09 17:54","pubTimestamp":1733738057,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nL4N3NA0LI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["600276","LU2148510915.USD","BK0012","BK0183","LU2488822045.USD","LU1064130708.USD","BK0188","BK0060","LU1328615791.USD","LU0405327148.USD","BK0196","BK0028","LU0405327494.USD","BK0239","LU1064131003.USD"],"gpt_icon":0},{"id":"2489421985","title":"Urothelial Carcinoma Drug of Hengrui Medicine's Unit Included in China's List of Breakthrough Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2489421985","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489421985?lang=en_us&edition=fundamental","pubTime":"2024-12-06 11:45","pubTimestamp":1733456727,"startTime":"0","endTime":"0","summary":"A urothelial carcinoma drug developed by Jiangsu Hengrui Medicine's  unit was included in the National Medical Products Administration's list of proposed breakthrough therapeutic products, according to a Shanghai Stock Exchange filing on Thursday.The SHR-A2102 injection of subsidiary Shanghai Hengrui Medicine was included in the list after it passed the regulator's review, the Chinese pharmaceutical company said.The company's shares rose 1% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1064130708.USD","BK0028","600276","LU1328615791.USD","LU0405327494.USD","LU1064131003.USD","LU2488822045.USD","BK0188","BK0060","BK0012","BK0196","LU2148510915.USD","BK0239","LU0405327148.USD","BK0183"],"gpt_icon":0},{"id":"2488795392","title":"Jiangsu Hengrui Medicine Gets Drug Registration for Anti-cancer Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2488795392","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488795392?lang=en_us&edition=fundamental","pubTime":"2024-12-03 12:40","pubTimestamp":1733200800,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  obtained drug registration for its fluzoparib capsules and apatinib mesylate tablets from China's drug administrator, according to a Monday filing with the Shanghai bourse.Fluzoparib is used for maintenance treatment of cancer, fallopian tube and primary peritoneal cancers. Apatinib mesylate is indicated for gastric adenocarcinoma and hepatocellular carcinoma.Shares of the pharmaceutical company were down 1% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2487309153","title":"Jiangsu Hengrui Medicine Sees Inclusion of 12 Drugs in National Medical Insurance Catalog; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2487309153","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487309153?lang=en_us&edition=fundamental","pubTime":"2024-11-29 12:33","pubTimestamp":1732854780,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  said 12 of its drugs were included in the national medical insurance catalog.Most of the included drugs were tablets, namely henggliflozin metformin, pregabalin, darcillis isethionate, revilutamide and proline, according to a Thursday filing with the Shanghai Stock Exchange.Also included were drugs for injection such as taijilidine fumarate, camrelizumab and esketamine hydrochloride as well as otacazole and fluzoparib capsules.The remaining inclusions were ondansetron orodispersible film and dexmedetomidine hydrochloride nasal spray.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2488822045.USD","LU1064130708.USD","LU1328615791.USD","BK0196","BK0239","LU0405327494.USD","BK0028","BK0060","BK0188","LU2148510915.USD","NHLD","600276","LU0405327148.USD","BK0012","BK0183","LU1064131003.USD"],"gpt_icon":0},{"id":"2486167248","title":"SPDB International HK Starts Jiangsu Hengrui Pharmaceuticals at Buy with 61 Yuan Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2486167248","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486167248?lang=en_us&edition=fundamental","pubTime":"2024-11-27 15:39","pubTimestamp":1732693175,"startTime":"0","endTime":"0","summary":"SPDB International HK Starts Jiangsu Hengrui Pharmaceuticals at Buy with 61 Yuan Price Target","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2486860421","title":"Hengrui Medicine's Unit Gets Regulatory Nod to Trial Atopic Dermatitis Drug; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486860421","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486860421?lang=en_us&edition=fundamental","pubTime":"2024-11-27 11:42","pubTimestamp":1732678970,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine's  unit, Guangdong Hengrui Medicine, will conduct clinical trials on its SHR-1819 injection after obtaining the approval of China's National Medical Products Administration, according to a Shanghai Stock Exchange disclosure on Tuesday.The pharmaceutical company will carry out phase Ib and phase II trials on the drug as a treatment for atopic dermatitis in children and adolescents aged six to 17 years old.The company's shares jumped less than 3% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","LU1064131003.USD","BK0028","BK0239","BK0188","LU1064130708.USD","LU2488822045.USD","BK0012","LU2148510915.USD","BK0196","600276","LU0405327148.USD","LU1328615791.USD","LU0405327494.USD","BK0060"],"gpt_icon":0},{"id":"2485236850","title":"Hengrui Medicine Units Get Clinical Trial Approval for Anti-Tumor Capsules","url":"https://stock-news.laohu8.com/highlight/detail?id=2485236850","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485236850?lang=en_us&edition=fundamental","pubTime":"2024-11-22 16:51","pubTimestamp":1732265484,"startTime":"0","endTime":"0","summary":"China's medical products administrator approved the clinical trial application of Jiangsu Hengrui Medicine  units' HRS-6208 anti-tumor capsules, according to a Thursday filing.Developed by Shanghai Hengrui Medicine and Shandong Shengdi Pharmaceutical, the capsules stop the phosphorylation activation or the addition of phosphates of cancer cells, helping prevent tumor cell proliferation.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2483362776","title":"Jiangsu Hengrui Medicine Gets State Administrator Approval for Autoimmune Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2483362776","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483362776?lang=en_us&edition=fundamental","pubTime":"2024-11-15 10:10","pubTimestamp":1731636618,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  subsidiary Guangdong Hengrui Medicine obtained China's administrator approval to conduct clinical trials for its SHR-2173 injection to treat immune thrombocytopenic purpura.SHR-2173 targets abnormally activated immune cells and is expected to reduce the level of autoantibodies, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company were down 1% in recent trade.Price : 48.11, Change: -0.34, Percent Change: -0.70%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BGHQF748.EUR","BK4585","LU0061475181.USD","BK4588","IE0034235188.USD","600276","BK4135","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU1883839398.USD","STT"],"gpt_icon":0},{"id":"2483364798","title":"Jiangsu Hengrui Medicine Unit Gets Regulatory Approval for Clinical Trial of Lipoprotein Disorder Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2483364798","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483364798?lang=en_us&edition=fundamental","pubTime":"2024-11-15 09:54","pubTimestamp":1731635664,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  subsidiary Fujian Shengdi Pharmaceutical obtained Chinese drug administrator approval to conduct clinical trials for its HRS-5632 injection.HRS-5632 has shown to \"effectively improve\" lipoprotein disorders after administration, according to a Thursday filing with the Shanghai bourse.Price : 48.40, Change: -0.050, Percent Change: -0.10%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2482242209","title":"Jiangsu Hengrui Medicine Gets State Administrator Approval for Tumor Drug Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2482242209","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482242209?lang=en_us&edition=fundamental","pubTime":"2024-11-11 11:56","pubTimestamp":1731297389,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  secured state administrator approval to conduct clinical trials for the treatment of tumors.The trials will use HRS-2189 tablets, HRS-5041 tablets, HRS-1358 tablets, HRS-8080 tablets, SHR-8068 injection, adebelimumab injection and HRS-6209 capsules, according to a Nov. 8 filing with the Shanghai bourse.Shares of Jiangsu Hengrui Medicine were down 1% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4135","600276","LU0061475181.USD","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE0034235188.USD","IE00B3QW5Z07.USD","LU1883839398.USD","BK4588","STT"],"gpt_icon":0},{"id":"2478312514","title":"Hengrui Medicine's Unit Gets Nod to Trial Hypertension Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2478312514","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478312514?lang=en_us&edition=fundamental","pubTime":"2024-10-28 14:23","pubTimestamp":1730096617,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine's  unit, Fujian Shengdi Pharmaceutical, will conduct clinical trials on hypertension drug after receiving approval from the Chinese drug administrator, according to a Shanghai Stock Exchange filing on Oct. 25.The pharmaceutical company invested 42.8 million yuan into the research and development of the drug, HRS-9563 injection, the filing said.Shares of the company rose more than 1% in recent trade.Price : 48.70, Change: +0.70, Percent Change: +1.46%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2478647089","title":"Jiangsu Hengrui Medicine Q3 Profit Up 2%, Revenue Climbs 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478647089","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478647089?lang=en_us&edition=fundamental","pubTime":"2024-10-25 11:42","pubTimestamp":1729827736,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  posted third-quarter net profit attributable to shareholders of 1.19 billion yuan, up 1.9% from the previous year.The pharmaceutical company's Q3 earnings per share rose 5.6% year over year to 0.19 yuan, according to a Thursday filing with the Shanghai bourse.Revenue climbed 13% to 6.59 billion yuan.Shares of Jiangsu Hengrui Medicine were down 2% in recent trade.Price : 47.89, Change: -0.78, Percent Change: -1.60%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276"],"gpt_icon":0},{"id":"2477045205","title":"Market Chatter: Jiangsu Hengrui Medicine Mulls $2 Billion Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2477045205","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477045205?lang=en_us&edition=fundamental","pubTime":"2024-10-24 17:59","pubTimestamp":1729763965,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  is considering a a secondary listing in Hong Kong that could raise $2 billion, Bloomberg News reported Thursday, citing people familiar with the matter.The Shanghai-listed drug manufacturer is now in talks with advisers regarding the IPO, which could take place as early as 2025, the report said, citing the sources.Price : 48.67, Change: -2.0, Percent Change: -3.99%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1064131003.USD","BK0012","LU1328615791.USD","LU0405327494.USD","LU1064130708.USD","600276","BK0239","BK0183","BK0028","LU2488822045.USD","BK0188","LU2148510915.USD","BK0060","LU0405327148.USD","BK0196"],"gpt_icon":0},{"id":"2477215508","title":"Hengrui Pharmaceuticals  Q3 Net Profit up 1.9% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2477215508","media":"THOMSON REUTERS","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477215508?lang=en_us&edition=fundamental","pubTime":"2024-10-24 16:53","pubTimestamp":1729759991,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241024:nL4N3M0110:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Hengrui Pharmaceuticals  Q3 Net Profit up 1.9% Y/Y","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0188","BK0012","BK0196","BK0183","LU2488822045.USD","600276","LU1064130708.USD","LU1064131003.USD","BK0060","BK0028","BK0239","LU1328615791.USD","LU0405327148.USD","LU0405327494.USD","LU2148510915.USD"],"gpt_icon":0},{"id":"2477803786","title":"Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 50.17 Yuan From 48.32 Yuan, Keeps at Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2477803786","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477803786?lang=en_us&edition=fundamental","pubTime":"2024-10-22 15:31","pubTimestamp":1729582311,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine (SHA:600276) has an average rating of outperform and price targets ranging from 41.90 yuan to 120 yuan, according to analysts polled by Capital IQ.(MT Newswires covers equity,","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600276","NMR"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","stockEarnings":[{"period":"1week","weight":-0.0073},{"period":"1month","weight":-0.0834},{"period":"3month","weight":0.0829},{"period":"6month","weight":0.1609},{"period":"1year","weight":0.0447},{"period":"ytd","weight":0.0277}],"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","perCapita":"15265股","boardName":"医药制造业","registeredCapital":"637900万元","compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0},{"period":"3month","weight":0.2307},{"period":"6month","weight":0.1234},{"period":"1year","weight":0.154},{"period":"ytd","weight":0.1321}],"survey":"　　江苏恒瑞医药股份有限公司主营业务涉及药品研发、生产和销售，主要产品是艾瑞昔布片、甲磺酸阿帕替尼片、硫培非格司亭注射液、马来酸吡咯替尼片、卡瑞利珠单抗、甲苯磺酸瑞马唑仑、氟唑帕利胶囊、海曲泊帕乙醇胺片、羟乙磺酸达尔西利片、脯氨酸恒格列净片、瑞维鲁胺片、阿得贝利单抗注射液、磷酸瑞格列汀片、富马酸泰吉利定注射液、林普利塞片、奥特康唑胶囊。报告期内，公司严格遵守环境保护法，依法持证排污，并按时缴纳环境保护税，环保信用评价等级为“绿色”，为“环保示范性企事业单位”及江苏省“绿色发展领军企业”，获得连云港经济技术开发区企业“环境保护质量奖”荣誉。","serverTime":1734906010957,"listedPrice":11.98,"stockholders":"417865人(较上一季度减少8.23%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.,600276,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票老虎,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票老虎国际,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股价,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股市,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票价格,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票交易,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票购买,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction